Sodium glucose co-transport 2 inhibitors for gout treatment

• Published in: Discoveries (Craiova, Romania) Romania), 2022-09, Vol.10 (3), p.e152-e152
• Main Authors: Somagutta, Manoj Kumar Reddy, Luvsannyam, Enkhmaa, Jain, Molly, Cuddapah, Gaurav Venkat, Pelluru, Sandeep, Mustafa, Nafisa, Nasereldin, Duaa S, Pendyala, Siva K, Jarapala, Nagendrababu, Padamati, Bhavani
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 2359-7232; 2359-7232
• DOI: 10.15190/d.2022.11

Hyperuricemia remains the most prevalent cause of gout. Gout patients present with joint inflammation and uric acid crystals deposition manifesting as tophi. The association of gout with increased risk of insulin resistance, diabetes, metabolic disorders, increased cardiometabolic risk, and kidney disease is well established. These factors influence the treatment plan, and current treatment options have limited cardiovascular risk reduction. So the need for novel treatments with a broad range of coverage for the complications is warranted. Sodium-glucose co-transporter 2 inhibitors are novel drugs approved for treating type-2 diabetes. They prevent glucose reabsorption and lower serum uric acid levels. Recently few studies have studied their association with reducing the risk of gout. They may help address the gout related complications through their recorded benefit with weight loss, improved insulin resistance, and cardiovascular benefits in recent studies. . SGLT2-Is may be useful to reduce the risk of gout in individuals with type 2 diabetes. Limited literature is available on the safety and efficacy of these novel antidiabetic drugs in patients with gout. This review is aimed to summarize the current knowledge on the role and effectiveness of novel antidiabetic medication as an early therapeutic option in gout patients.